Pravastatin reduces fibrinogen receptor gpIIIa on platelet‐derived microparticles in patients with type 2 diabetes
暂无分享,去创建一个
P. Reitsma | D. Sommeijer | D. W. SOMMEIJER | K. JOOP | A. LEYTE | P. H. REITSMA | H.TEN CATE | A. Leyte | H. Cate | K. Joop
[1] C. Esmon,et al. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. Studies in Scott syndrome: an isolated defect in platelet procoagulant activity. , 1989, The Journal of biological chemistry.
[2] G. Davı̀,et al. Inhibition of throm☐ane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia , 1994 .
[3] S. Nomura,et al. Platelet-derived microparticles may influence the development of atherosclerosis in diabetes mellitus. , 1995, Atherosclerosis.
[4] D. Erkelens,et al. Insulin resistance syndrome and type 2 diabetes mellitus. , 2001, The American journal of cardiology.
[5] E. Dajani,et al. Statins, platelet aggregation and coronary heart disease. , 2002, Journal of the Association for Academic Minority Physicians : the official publication of the Association for Academic Minority Physicians.
[6] Richard Barnett,et al. Diabetes mellitus. , 1993, The Medical journal of Australia.
[7] A. Goodall,et al. Evaluation of Whole Blood Flow Cytometric Detection of Platelet Bound Fibrinogen on Normal Subjects and Patients with Activated Platelets , 1993, Thrombosis and Haemostasis.
[8] J. Frohlich,et al. Dyslipidaemia and coagulation defects of insulin resistance. , 2000, International journal of clinical practice. Supplement.
[9] P. Reitsma,et al. Anti-inflammatory and anticoagulant effects of pravastatin in patients with type 2 diabetes. , 2004, Diabetes care.
[10] A. Simon,et al. Platelet cytosolic Ca2+ and membrane dynamics in patients with primary hypercholesterolemia. Effects of pravastatin. , 1995, Arteriosclerosis, thrombosis, and vascular biology.
[11] R. Nieuwland,et al. Elevated Numbers of Tissue-Factor Exposing Microparticles Correlate With Components of the Metabolic Syndrome in Uncomplicated Type 2 Diabetes Mellitus , 2002, Circulation.
[12] A. Michael,et al. Reduced platelet aggregation after fluvastatin therapy is associated with altered platelet lipid composition and drug binding to the platelets. , 2003, British journal of clinical pharmacology.
[13] B. Davis,et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. , 1998, Circulation.
[14] Terje R Pedersen,et al. Cholesterol Lowering With Simvastatin Improves Prognosis of Diabetic Patients With Coronary Heart Disease: A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) , 1997, Diabetes Care.
[15] D. Nie,et al. Inhibition of platelet aggregation and expression of alpha granule membrane protein 140 and thromboxane B2 with pravastatin therapy for hypercholesterolemia. , 2002, Journal of the Association for Academic Minority Physicians : the official publication of the Association for Academic Minority Physicians.
[16] K. Maquelin,et al. Cell-derived microparticles generated in patients during cardiopulmonary bypass are highly procoagulant. , 1997, Circulation.
[17] H. Parving,et al. Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: progressive, interrelated, and independently associated with risk of death. , 2002, Diabetes.
[18] A. Palazzuoli,et al. Time‐dependent effect of statins on platelet function in hypercholesterolaemia , 2002, European journal of clinical investigation.
[19] R. Westendorp,et al. Cellular origin and procoagulant properties of microparticles in meningococcal sepsis. , 2000, Blood.
[20] R. Nieuwland,et al. Microparticles in cardiovascular diseases. , 2003, Cardiovascular research.
[21] V. Petrov,et al. Influence of cholesterol-lowering on plasma membrane lipids and function. , 1996, Methods and findings in experimental and clinical pharmacology.